abrdn plc Has $91.83 Million Stock Position in AstraZeneca PLC (NASDAQ:AZN)

abrdn plc raised its holdings in AstraZeneca PLC (NASDAQ:AZN) by 2.9% during the 4th quarter, Holdings Channel.com reports. The institutional investor owned 1,401,489 shares of the company’s stock after acquiring an additional 39,173 shares during the quarter. abrdn plc’s holdings in AstraZeneca were worth $91,826,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently modified their holdings of the company. McClarren Financial Advisors Inc. lifted its position in shares of AstraZeneca by 320.8% during the 3rd quarter. McClarren Financial Advisors Inc. now owns 324 shares of the company’s stock valued at $25,000 after acquiring an additional 247 shares during the period. Capital Performance Advisors LLP bought a new stake in AstraZeneca in the third quarter valued at $28,000. Ashton Thomas Securities LLC acquired a new position in shares of AstraZeneca during the third quarter valued at about $45,000. Albion Financial Group UT boosted its position in shares of AstraZeneca by 68.9% during the 4th quarter. Albion Financial Group UT now owns 608 shares of the company’s stock worth $40,000 after purchasing an additional 248 shares in the last quarter. Finally, Hollencrest Capital Management grew its stake in shares of AstraZeneca by 38.4% in the 3rd quarter. Hollencrest Capital Management now owns 692 shares of the company’s stock valued at $54,000 after buying an additional 192 shares during the period. 20.35% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

AZN has been the topic of a number of research reports. UBS Group raised AstraZeneca from a “sell” rating to a “neutral” rating in a research note on Wednesday, November 20th. Deutsche Bank Aktiengesellschaft upgraded AstraZeneca from a “sell” rating to a “hold” rating in a report on Wednesday, November 6th. Two investment analysts have rated the stock with a hold rating, five have assigned a buy rating and two have assigned a strong buy rating to the stock. Based on data from MarketBeat, AstraZeneca presently has a consensus rating of “Buy” and an average target price of $89.75.

AstraZeneca Stock Performance

Shares of AZN opened at $68.96 on Wednesday. The firm has a market capitalization of $213.85 billion, a P/E ratio of 33.00, a P/E/G ratio of 1.18 and a beta of 0.46. AstraZeneca PLC has a 52 week low of $60.47 and a 52 week high of $87.68. The stock has a 50 day moving average price of $67.15 and a two-hundred day moving average price of $73.79. The company has a debt-to-equity ratio of 0.71, a quick ratio of 0.71 and a current ratio of 0.93.

AstraZeneca (NASDAQ:AZN) last announced its quarterly earnings results on Tuesday, November 12th. The company reported $1.04 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.01 by $0.03. AstraZeneca had a return on equity of 30.01% and a net margin of 12.68%. The business had revenue of $13.57 billion during the quarter, compared to the consensus estimate of $13.08 billion. During the same quarter in the prior year, the company posted $0.87 earnings per share. AstraZeneca’s revenue was up 18.0% compared to the same quarter last year. Equities analysts forecast that AstraZeneca PLC will post 4.13 earnings per share for the current fiscal year.

AstraZeneca Company Profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company’s marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.